Success Metrics

Clinical Success Rate
80.6%

Based on 100 completed trials

Completion Rate
81%(100/124)
Active Trials
26(13%)
Results Posted
40%(40 trials)
Terminated
24(12%)

Phase Distribution

Ph phase_1
28
13%
Ph phase_3
15
7%
Ph not_applicable
33
16%
Ph early_phase_1
11
5%
Ph phase_2
74
36%
Ph phase_4
41
20%

Phase Distribution

39

Early Stage

74

Mid Stage

56

Late Stage

Phase Distribution202 total trials
Early Phase 1First-in-human
11(5.4%)
Phase 1Safety & dosage
28(13.9%)
Phase 2Efficacy & side effects
74(36.6%)
Phase 3Large-scale testing
15(7.4%)
Phase 4Post-market surveillance
41(20.3%)
N/ANon-phased studies
33(16.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.2%

100 of 133 finished

Non-Completion Rate

24.8%

33 ended early

Currently Active

26

trials recruiting

Total Trials

208

all time

Status Distribution
Active(37)
Completed(100)
Terminated(33)
Other(38)

Detailed Status

Completed100
unknown38
Terminated24
Recruiting23
Withdrawn9
Not yet recruiting8

Development Timeline

Analytics

Development Status

Total Trials
208
Active
26
Success Rate
80.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (5.4%)
Phase 128 (13.9%)
Phase 274 (36.6%)
Phase 315 (7.4%)
Phase 441 (20.3%)
N/A33 (16.3%)

Trials by Status

unknown3818%
completed10048%
active_not_recruiting31%
withdrawn94%
not_yet_recruiting84%
terminated2412%
enrolling_by_invitation31%
recruiting2311%

Recent Activity

Clinical Trials (208)

Showing 20 of 208 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT05853627Phase 4

Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery

Recruiting
NCT05587361Phase 4

Beta-Adrenergic Modulation of Drug Cue Reactivity

Recruiting
NCT03079921Early Phase 1

Adrenergic System in Islet Transplantation

Completed
NCT07549906Phase 2

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Not Yet Recruiting
NCT07353294Phase 1

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Enrolling By Invitation
NCT06120140Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Recruiting
NCT07091279Phase 2

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

Recruiting
NCT06798363Phase 2

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Recruiting
NCT05741164Phase 2

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Not Yet Recruiting
NCT05561751Phase 2

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Completed
NCT05797662Phase 2

A Study of Propranolol to Treat Kaposi Sarcoma

Not Yet Recruiting
NCT07354126Not Applicable

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine

Recruiting
NCT07352228Phase 4

Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices

Enrolling By Invitation
NCT01988883Early Phase 1

Modafinil and Cognitive Function in POTS

Active Not Recruiting
NCT04682158Phase 2

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Recruiting
NCT07271485Early Phase 1

Propranolol for Misophonia

Recruiting
NCT05312255Not Applicable

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Recruiting
NCT04837261

Shortening Duration of Antiarrhythmic Medication for SVT in Infants

Completed
NCT06263452Phase 4

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
208